Skip to main content
Premium Trial:

Request an Annual Quote

As Incyte Predicts Weaker Year, Stock Falls Sharply

NEW YORK, Sept. 4-Citing slowdowns in database subscriptions and licensing deals, Incyte Genomics today downgraded its financial outlook for the remainder of the fiscal year.


The company said today that it expects its net losses for the year to fall between $75 million to $98 million, considerably more than the $65 million to $85 million loss estimate that Incyte previously announced.


Incyte's revenue guidance for the fiscal year now falls between $100 million and $130 million, down from the $130 million to $150 million range.


Shares of the company were trading at $4.36 Wednesday morning, down more than 22 percent from yesterday's close of $5.63.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.